-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Applying Genome Engineering to Enhance CAR T Cell Responses to Blood Cancers.

Program: Scientific Program
Session: Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy
Sunday, December 10, 2023, 9:30 AM-11:05 AM

Carl June, MD

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA

Disclosures: June: AC Immune: Membership on an entity's Board of Directors or advisory committees; BluesphereBio: Membership on an entity's Board of Directors or advisory committees; Cabaletta: Membership on an entity's Board of Directors or advisory committees; Carisma: Membership on an entity's Board of Directors or advisory committees; Cartography: Membership on an entity's Board of Directors or advisory committees; Cellares: Membership on an entity's Board of Directors or advisory committees; Celldex: Membership on an entity's Board of Directors or advisory committees; Decheng: Membership on an entity's Board of Directors or advisory committees; Poseida: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Verismo: Membership on an entity's Board of Directors or advisory committees; WIRB-Copernicus: Membership on an entity's Board of Directors or advisory committees; Danaher: Membership on an entity's Board of Directors or advisory committees.

<< Previous Presentation | Next Presentation